English(EN) Today, LifeBioSciences team confirmed the first patient has been dosed with an epigenetic restoration drug candidate targeting optic neuropathies. "An exciting milestone"

Life BioSciences 启动视神经病变药物的I期试验

作者 PulseAugur 编辑部 · [1 个来源] · 2026-06-09 21:02

Life BioSciences 宣布了一个重要的里程碑：首位患者已接受ER-100的I期临床试验给药。ER-100是一种靶向视神经病变的表观遗传修复候选药物。视神经病变是一组损害视神经并可能导致永久性视力丧失的疾病。该试验将评估ER-100的安全性与耐受性，同时评估其对视功能的影响。 AI

排序理由该集群报告了一项新候选药物的I期临床试验的启动，属于研究范畴。[lever_c_demoted from research: ic=1 ai=0.1]

在 r/singularity 阅读 →

其他

AI 生成摘要 · Google Gemini · 来自 1 个来源。我们如何撰写摘要 →

报道来源 [1]

r/singularity TIER_2 English(EN) · /u/Distinct-Question-16 · 2026-06-09 21:02

Today, LifeBioSciences team confirmed the first patient has been dosed with an epigenetic restoration drug candidate targeting optic neuropathies. "An exciting milestone"

<table> <tr><td> <a href="https://www.reddit.com/r/singularity/comments/1u1hr8w/today_lifebiosciences_team_confirmed_the_first/"> <img alt="Today, LifeBioSciences team confirmed the first patient has been dosed with an epigenetic restoration drug candidate targeting optic neuropa…

报道来源 [1]

Today, LifeBioSciences team confirmed the first patient has been dosed with an epigenetic restoration drug candidate targeting optic neuropathies. "An exciting milestone"

相关实体

相关话题